Liu Shi Xin

Nuova
40 anni di esperienza
Località: Cina, Xiamen
Clinica:Ospedale Xiamen Humanity
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
Mostra di più

Nuova

Visita dal medico

Prezzo su richiesta

Bookimed Insights: Principali specialisti in Cancro rettale in Cina (2026)

Bookimed ha coordinato 53704 richieste di trattamento per Cancro rettale in Cina, collaborando con 1 specialisti di alto livello. I medici in questa tabella sono selezionati in base alle loro credenziali internazionali, esperienza clinica e risultati dei pazienti. La classifica del 2026 è composta da dati verificati su casi reali e dai programmi attuali delle nostre cliniche partner.

Classifica	Medico	esperienza	Buona scelta per	Cosa li distingue	Clinica e posizione	Consulto

FAQ

Queste domande frequenti provengono da pazienti reali che cercano assistenza medica tramite Bookimed. Le risposte sono fornite da coordinatori medici esperti e rappresentanti affidabili delle cliniche.

What are the primary treatment options available in China for rectal cancer?

Rectal cancer treatment in China centers on total mesorectal excision (TME) and minimally invasive surgeries. Top oncology hospitals in Guangzhou and Shanghai utilize the da Vinci robotic system. Specialized centers integrate cryosurgery, NanoKnife, and immunotherapy for advanced cases within JCI-accredited facilities.

Surgical gold standard: Surgeons perform total mesorectal excision (TME) to minimize recurrence risk.
Minimally invasive access: Over 56% of procedures use laparoscopic or robotic-assisted techniques.
Advanced thermal therapies: Clinics like Fuda Hospital offer cryosurgery and microwave hyperthermia.
Precise radiation: CyberKnife M6 systems provide non-invasive stereotactic radiosurgery for targeted tumor control.

Bookimed Expert Insight: Patient data shows a preference for Guangzhou-based centers due to their expertise in non-traditional therapies. Fuda Cancer Hospital has served over 30,000 international patients. They specialize in combining minimally invasive methods like NanoKnife with standard oncology protocols. This approach provides options for cases where conventional surgery is not the primary choice.

Patient Consensus: Patients emphasize verifying tumor genetics like MSI and KRAS early to access targeted drugs. Many note that treatment starts much faster in China than in Western countries.

Can rectal cancer be treated in China without needing a permanent colostomy bag?

Rectal cancer patients in China can avoid a permanent colostomy bag through advanced sphincter-preserving surgeries like Intersphincteric Resection (ISR). Major centers report that 75% of low rectal cancer cases now undergo successful anal preservation. Techniques like Neoadjuvant therapy shrink tumors to ensure safer removal while maintaining natural bowel function.

Surgical techniques: Low Anterior Resection (LAR) and coloanal anastomosis allow internal reconnection without a permanent bag.
Advanced technology: Surgeons use the Da Vinci robotic system for high-precision pelvic muscle and nerve preservation.
Minimally invasive options: Laparoscopic total mesorectal excision (TME) reduces tissue trauma and supports faster recovery times.
Non-surgical approach: Select patients achieving complete clinical response via chemoradiation may follow a watch and wait protocol.

Bookimed Expert Insight: Clinical data indicates that elite JCI-accredited facilities like Fuda Cancer Hospital utilize over 10 types of minimally invasive therapies. Patients often overlook that while surgery is standard, combining it with local treatments like Cryosurgery or NanoKnife can improve margins. This multimodal approach specifically helps in preserving the sphincter for tumors located very close to the anal verge.

Patient Consensus: Patients emphasize the importance of seeking second opinions at tier-1 hospitals to avoid rushed permanent colostomies recommended by local clinics. They note that while an ileostomy may be necessary, it is typically temporary for 6 to 16 weeks during healing.

How widely available is robotic surgery for rectal cancer in China and what are its proven advantages?

Robotic surgery for rectal cancer is highly accessible in Chinas top-tier tertiary hospitals. It accounts for nearly 49% of rectal procedures as of 2020. Major centers in Guangzhou, Shanghai, and Beijing utilize the da Vinci system and domestic platforms like MicroPort Toumai for precise tumor removal.

Surgical precision: 3D high-definition vision allows for navigating the narrow pelvic cavity.
Nerve preservation: Robotic assistance helps preserve nerves to maintain urinary and sexual function.
Preservation rates: Increased success in sphincter preservation helps many patients avoid permanent colostomy.
Clinical outcomes: Robotic methods result in less blood loss and fewer conversions to open surgery.

Bookimed Expert Insight: While elite centers like Fuda Cancer Hospital focus on minimally invasive cryosurgery and NanoKnife, robotic platforms are concentrated in large academic hospitals. Data shows these tertiary centers perform thousands of cases. This confirms high surgical proficiency in complex pelvic resections.

Patient Consensus: Patients note that robotic surgery significantly shortens hospital stays compared to open procedures. Many emphasize that traveling to major cities like Guangzhou is necessary to access this technology.

Which innovative targeted or immunotherapy drugs are accessible for rectal cancer patients in China?

Rectal cancer patients in China access innovative immunotherapy drugs like Sintilimab, Toripalimab, and Pembrolizumab. Leading targeted therapies include Fruquintinib and Cetuximab. These medications target specific molecular markers such as MSI-H/dMMR or RAS wild-type. Facilities like Fuda Cancer Hospital provide advanced minimally invasive options alongside these pharmacological treatments.

Immune inhibitors: Sintilimab and Toripalimab are domestically developed PD-1 inhibitors for MSI-H cases.
Targeted therapy: Fruquintinib treats metastatic cases by blocking VEGFR 1, 2, and 3 pathways.
EGFR blockers: Cetuximab is accessible for patients with RAS wild-type left-sided rectal tumors.
Advanced delivery: Clinics offer vascular interventional therapy to deliver medications directly to tumor sites.

Bookimed Expert Insight: While global drugs like Pembrolizumab are available, local innovations like Fruquintinib offer a significant advantage. Data from JCI-accredited facilities like Fuda Cancer Hospital shows they often combine these drugs with cryosurgery. This multi-modal approach serves over 30,000 international patients. Clinical packages for advanced radiation, like CyberKnife at Jinshazhou Hospital, may cost approximately 56,000 CNY (around $7,750). These local options often provide faster access than waiting for international trial spots in Tier-1 cities.

Patient Consensus: Patients emphasize getting MSI and PD-L1 testing early to unlock drug options. Many note that Fruquintinib is an effective third-line choice and more affordable than imported alternatives.

Is it safe to integrate Traditional Chinese Medicine (TCM) with standard Western rectal-cancer treatment?

Integrating Traditional Chinese Medicine with Western rectal cancer treatment is generally safe under professional supervision. Leading Chinese centers like Fuda Cancer Hospital use integrated protocols to reduce chemotherapy side effects. Coordinated care helps manage nausea, protects immune function, and improves 5-year survival rates.

Side effect management: TCM alleviates chemotherapy-induced nausea, vomiting, and peripheral nerve toxicity.
Immune support: Combined therapies help stabilize white blood cell counts and CD4+ cells.
Expert coordination: Certified clinicians must monitor herb-drug interactions to prevent reduced chemotherapy efficacy.
Advanced technology: Clinics integrate TCM alongside CyberKnife M6 and Da Vinci robotic systems.

Bookimed Expert Insight: Patients seeking integrated care should prioritize hospitals affiliated with major universities. For example, Jinshazhou Hospital is part of the Guangzhou University of Chinese Medicine. This connection ensures TCM protocols are vetted by academic tumor boards. Packages here, like CyberKnife radiosurgery for approximately $7,850, focus on high-tech Western precision. This confirms that TCM is treated as a supportive specialty rather than a primary replacement.

Patient Consensus: Patients emphasize using TCM only for symptom relief after clearing specific herbs with their Western oncologist. Many note that tracking bloodwork rigorously is essential to catch any rare herb-induced kidney stress early.

I migliori medici per il trattamento di Cancro rettale a Xiamen - TOP-1 medici

Richiedi preventivi da 3 migliori specialisti di in Cina